Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

Anti-cancer Drugs
J M Meerum TerwogtJ H Beijnen

Abstract

Intravenous administration of paclitaxel is hindered by poor water solubility of the drug. Currently, paclitaxel is dissolved in a mixture of ethanol and Cremophor EL; however, this formulation (Taxol) is associated with significant side effects, which are considered to be related to the pharmaceutical vehicle. A new polymer-conjugated derivative of paclitaxel, PNU166945, was investigated in a dose-finding phase I study to document toxicity and pharmacokinetics. A clinical phase I study was initiated in patients with refractory solid tumors. PNU16645 was administered as a 1-h infusion every 3 weeks at a starting dose of 80 mg/m(2), as paclitaxel equivalents. Pharmacokinetics of polymer-bound and released paclitaxel were determined during the first course. Twelve patients in total were enrolled in the study. The highest dose level was 196 mg/m(2), at which we did not observe any dose-limiting toxicities. Hematologic toxicity of PNU166945 was mild and dose independent. One patient developed a grade 3 neurotoxicity. A partial response was observed in one patient with advanced breast cancer. PNU166945 displayed a linear pharmacokinetic behavior for the bound fraction as well as for released paclitaxel. The study was discontinued pr...Continue Reading

References

Jun 1, 1992·Anti-cancer Drugs·R Duncan
Jan 1, 1995·Cancer Investigation·M T HuizingJ H Beijnen
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L GianniM J Egorin
Apr 13, 1995·The New England Journal of Medicine·E K Rowinsky, R C Donehower
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M T HuizingJ H Beijnen
May 1, 1994·The Annals of Pharmacotherapy·R T Dorr
Jan 1, 1995·Breast Cancer Research and Treatment·H P SinnH Ponta
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M T HuizingJ H Beijnen
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A W TolcherW Slichenmyer

❮ Previous
Next ❯

Citations

Nov 27, 2004·Cancer Chemotherapy and Pharmacology·Saadia HassanElin Lindhagen
Aug 27, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anita BogomilovaLaura Schreiner
Jun 19, 2012·Chemistry of Materials : a Publication of the American Chemical Society·Nate Larson, Hamidreza Ghandehari
Nov 15, 2011·Molecular Pharmaceutics·Yashveer SinghPatrick J Sinko
Jan 21, 2012·Molecular Pharmaceutics·Jongdoo LimEric E Simanek
Aug 11, 2006·Nature Reviews. Cancer·Ruth Duncan
Jun 13, 2009·Chemical Communications : Chem Comm·Chalermchai KhemtongJinming Gao
Aug 21, 2008·Proceedings of the National Academy of Sciences of the United States of America·Elena A DubikovskayaPaul A Wender
Mar 7, 2002·Current Opinion in Oncology·Evan AlleyLynn Schuchter
Aug 21, 2002·Anti-cancer Drugs·Walter J LoosAlex Sparreboom
Jan 10, 2014·International Journal of Nanomedicine·Lulu CaiLijuan Chen
Jul 8, 2003·Clinical Pharmacokinetics·Albert J ten TijeAlex Sparreboom
Sep 21, 2006·Clinical Pharmacokinetics·Suphiya Parveen, Sanjeeb K Sahoo
Jan 8, 2013·International Journal of Oncology·Yan-Jun ZhongYan Li
May 7, 2011·Theranostics·Mingqian Tan, Zheng-Rong Lu
Aug 31, 2012·Nanomedicine·Suwussa BamrungsapWeihong Tan
Mar 13, 2013·Nanomedicine·Catherine A SchützUNKNOWN NanoImpactNet Consortium
Aug 26, 2010·Nanomedicine·Joaquin SanchisMaría J Vicent
May 25, 2012·Pharmaceutical Research·Orazio VittorioNevio Picci
Aug 19, 2009·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Xu WangDong M Shin
Dec 29, 2004·Journal of Drug Targeting·María J VicentRuth Duncan
Dec 15, 2010·Expert Opinion on Drug Delivery·Franco DosioLuigi Cattel
Jan 14, 2011·Expert Opinion on Drug Delivery·Hongbin ZhangHuai Yang
Feb 28, 2015·Journal of Drug Targeting· ParamjotNeeraj Mishra
Jun 28, 2007·Expert Opinion on Investigational Drugs·Felix KratzAndré Warnecke
Dec 8, 2007·Journal of Pharmaceutical Sciences·Jubo LiuChristine Allen
Dec 30, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Andreas WickiJörg Huwyler
Nov 6, 2012·Advanced Drug Delivery Reviews·Jindřich Kopeček
Aug 25, 2012·Advanced Drug Delivery Reviews·Xue-Qing ZhangOmid C Farokhzad
Oct 13, 2006·Neoplasia : an International Journal for Oncology Research·Twan LammersGert Storm
Jan 18, 2011·Advanced Drug Delivery Reviews·L BildsteinP Couvreur
Aug 17, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ping ZhouYing Chau
Jan 5, 2010·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jason H SakamotoMauro Ferrari
Aug 25, 2009·Advanced Drug Delivery Reviews·Francesca Greco, María J Vicent
Aug 25, 2009·Advanced Drug Delivery Reviews·Ehud Segal, Ronit Satchi-Fainaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.